
C Diff Update: The Latest News and Research
Here is a review of the most up-to-date information around the infection.
There has been some interesting news, research, and even federal legislation around this healthcare-associated infection. Read the latest on
A hospital CDI intervention program that supported patients via an ID specialist demonstrated clinical benefits compared to another hospital where patients were followed by providers of any specialty.
A bill in the House of Representatives was just introduced with the advocacy of the Peggy Lillis Foundation in hopes of bringing more recognition and research to the healthcare-associated infection.
A secondary analysis of a randomized trial points to limited benefits on the microbiota.
In additional analyses, the novel antibiotic, ibezapolstat, demonstrated favorable gut microbiome changes including increased relative proportion of Actinobacteria in ibezapolstat-treated patients with C diff Infection (CDI).
A Florida hospital takes a novel approach for the healthcare-associated infection and reduced inappropriate testing by setting up guidelines.




























































































































































































